£96.0M
The biotechnology firm has raised £96m in new capital to advance its gene therapy pipeline and manufacturing capabilities.
£96.0MTotal raised
Freeline is a biotechnology company focused on developing curative gene therapies for chronic systemic diseases. The clinical stage business targets liver based AAV gene therapies to provide potential functional cures.
Categories
Team
Theresa Heggie
CEO
Theresa brings extensive board and executive experience across biotechnology and therapeutics companies. Her career includes serving as chief executive officer at Freeline and interim chief executive officer at Hybridize Therapeutics, alongside multiple board mandates.
LinkedIn